Journal for ImmunoTherapy of Cancer · 2026-05-08
PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer?
Phrase rank #1 · DOI 10.1136/jitc-2025-014088
Other observed topics
CAR
Observed in 144 articles across 13 journals.
Latest share0.04%
Change vs baseline-0.13 pp
Months observed12
Latest monthJul 2026
Portfolio article share
Attention over this snapshot
13 monthly points
Journal breadth
Where it appears
- Journal for ImmunoTherapy of Cancer123
- Lupus Science & Medicine6
- Journal of Scleroderma and Related Disorders3
- RMD Open2
- Sexually Transmitted Infections2
- Archives of Disease in Childhood1
- BMJ Case Reports1
- BMJ Military Health1
- BMJ Supportive & Palliative Care1
- Drug and Therapeutics Bulletin1
- European Journal of Hospital Pharmacy1
- Gut1
Co-occurrence
Explore nearby topics
Inspect the source signal
Article evidence
30 high-ranking examples
Journal for ImmunoTherapy of Cancer · 2026-01-16
CAR T cells: the missing piece needed to improve outcomes for children with cancer?
Phrase rank #1 · DOI 10.1136/jitc-2025-013325
Journal for ImmunoTherapy of Cancer · 2026-01-09
Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations
Phrase rank #1 · DOI 10.1136/jitc-2025-012318
Journal for ImmunoTherapy of Cancer · 2025-11-19
CD28 signaling complexes are correlated with patient outcomes in anti-CD19 41BB-costimulation CAR T cell therapy
Phrase rank #1 · DOI 10.1136/jitc-2025-013023
Journal for ImmunoTherapy of Cancer · 2025-11-13
Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival
Phrase rank #1 · DOI 10.1136/jitc-2025-011971
Journal for ImmunoTherapy of Cancer · 2025-11-04
1019 Discovery of lineage specific regulatory elements for development of in vivo CAR immune cell therapy via hematopoietic stem cell engineering
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1019
Journal for ImmunoTherapy of Cancer · 2025-11-04
240 WAY-102: an in vivo lentiviral dual-armored CLDN18.2 CAR T engineered for long-term durability & cytotoxicity in the tumor microenvironment
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0240
Journal for ImmunoTherapy of Cancer · 2025-11-04
1015 Early bystander effect of vaccine boosting of CAR T cells reinvigorates endogenous anti-tumor T cell immunity to regress pancreatic cancer
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1015
Journal for ImmunoTherapy of Cancer · 2025-11-04
394 Combination of a tumor-specific virus and CAR T to specifically and universally target tumors of epithelial origin and overcome challenges of the tumor microenvironment
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0394
Journal for ImmunoTherapy of Cancer · 2025-11-04
267 Pre-clinical evaluation of a new B7-H3 CAR in a human glioblastoma model
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0267
Journal for ImmunoTherapy of Cancer · 2025-11-04
248 Exploitation of endogenous TCR signaling using an oncolytic virus for modulation of CAR T phenotype and function against solid tumors
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0248
Journal for ImmunoTherapy of Cancer · 2025-11-04
283 Functional profiling of CAR T cells using high-dimensional CyTOF: integrating cytokine, transcription factor and immune checkpoint marker signatures
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0283
Journal for ImmunoTherapy of Cancer · 2025-11-04
393 DISP-10 is a novel CAR T and tumor-specific virus combination undergoing clinical development that is designed for use as a universal treatment for epithelial tumors
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0393
Journal for ImmunoTherapy of Cancer · 2025-11-04
294 NOT-gated chimeric antigen receptor (CAR) T cells kill acute myeloid leukemia and spare endothelial cells via VE-cadherin inhibitory CAR
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0294
Journal for ImmunoTherapy of Cancer · 2025-11-04
285 A non-viral engineering platform for rapid CAR T cell manufacturing and delivery of complex genetic payloads
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0285
Journal for ImmunoTherapy of Cancer · 2025-11-04
298 A novel NK-cell based split-signaling killer immunoglobulin receptor (KIR)-based CAR T targeting mesothelin, SynKIR-110, shows increased safety profile and increased efficacy in vitro and in vivo
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0298
Journal for ImmunoTherapy of Cancer · 2025-11-04
237 Dual CD123/B7-H3 CAR T cell therapy reprograms the tumor microenvironment and enhances immunity in DIPG
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0237
Journal for ImmunoTherapy of Cancer · 2025-11-04
286 Advancing non-viral T cell engineering through efficient integration of CAR constructs via electroporation of CRISPR or transposon-mediated gene editing tools
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0286
Journal for ImmunoTherapy of Cancer · 2025-11-04
1126 Rational CAR T cell design via attention-based multiple instance learning of infusion product scRNA-seq data
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1126
Journal for ImmunoTherapy of Cancer · 2025-11-04
212 Development of EPHA2 CAR T cell therapy for solid tumors
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0212
Journal for ImmunoTherapy of Cancer · 2025-11-04
268 Regional B7-H3 CAR cell therapy and liver-directed radiation for pancreatic cancer liver metastases
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0268
Journal for ImmunoTherapy of Cancer · 2025-11-04
557 Evaluation of huCART19-IL18 manufactured using Synecta™ CDNP technology to improve CAR-T yield and consistency in cohort D of an ongoing phase I study (NCT04684563)
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0557
Journal for ImmunoTherapy of Cancer · 2025-11-04
365 Single-cell transcriptional profiles of cilta-cel and ide-cel associate with response in multiple myeloma
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0365
Journal for ImmunoTherapy of Cancer · 2025-11-04
302 In vivo HSC engineering with VLPs generates lineage-restricted, multiplexed CAR-M, NK, and T cells to cooperatively mediate robust and durable solid tumor control in pre-clinical models
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0302
Journal for ImmunoTherapy of Cancer · 2025-11-04
675 Radiopharmaceutical therapy enhances CAR T-cell activity against neuroblastoma by tumor sensitization and tumor microenvironment remodeling
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0675
Journal for ImmunoTherapy of Cancer · 2025-11-04
388 Antigen-dependent CAR T cell toxicity is amplified by neutrophil-mediated crosstalk in epithelial cancers
Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.0388
Journal for ImmunoTherapy of Cancer · 2025-07-28
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
Phrase rank #1 · DOI 10.1136/jitc-2025-011807
Journal for ImmunoTherapy of Cancer · 2025-07-25
hCCL19-expressing recombinant Newcastle disease virus boosts CAR T cell infiltration and efficacy in solid tumor
Phrase rank #1 · DOI 10.1136/jitc-2025-011783
Journal of Scleroderma and Related Disorders · 2026-06-05
P.248 Anti-CD19 CAR T cell therapy in systemic sclerosis - update on seven patients from tuebingen
Phrase rank #2 · DOI 10.1136/JSRD-2026-SSWC.291
Journal for ImmunoTherapy of Cancer · 2026-06-05
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results
Phrase rank #2 · DOI 10.1136/jitc-2026-015296